Amanote Research
Register
Sign In
Pcn226 - Biosimilars and the Regulation of Oncological Preparations in Germany
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.308
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
A. Walendzik
J. Wasem
S. Altin
C. Bauer
U. May
Publisher
Elsevier BV
Related search
Demystifying Biosimilars: Development, Regulation and Clinical Use
Future Oncology
Medicine
Cancer Research
Oncology
Recommendations for the Regulation of Biosimilars and Their Implementation in Latin America
GaBI Journal
Drug Guides
Pharmacy
Stock-Exchange Regulation in Germany
Journal of Political Economy
Economics
Econometrics
Assessing Physician and Patient Acceptance of Infliximab Biosimilars in Rheumatoid Arthritis, Ankylosing Spondyloarthritis and Psoriatic Arthritis Across Germany
Patient Preference and Adherence
Pharmacology
Health Policy
Medicine
Toxicology
Social Sciences
Pharmaceutics
Outsiders Within: Framing and Regulation of Headscarves in France, Germany and the Netherlands
Social Inclusion
Social Psychology
Sociology
Political Science
Biosimilars in Medicine
Era's journal of medical research
Biosimilars
ESMO Open
Cancer Research
Oncology
Biosimilars: Approval and Acceptance?
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Biosimilars 2.0
mAbs
Allergy
Immunology
